In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marnac, Inc.

Latest From Marnac, Inc.

Cantargia Confident About Nadunolimab’s Prospects For Pancreatic Cancer

The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.

Cancer Financing

Finance Watch: Biotech Stocks Stabilize At The End Of A Rocky Week

Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.

Financing Business Strategies

Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Tech Transfer Round-Up Deals

Be Bio’s New $130m Raise Will Advance B-Cell Therapies Toward The Clinic

Biotech is developing engineered B-cell therapeutics for rare diseases and cancer. They should offer greater duration and better tolerability than T-cell therapies, the company claims.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register